The apoptotic pathway: A target for therapy in chronic lymphocytic leukemia

Hematological Oncology

Volumn 18, Issue 3, 2000, Pages 87-98

  Bentley, D P ^a,b   Pepper, C J ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Chronic lymphocytic leukemia

Indexed keywords

CASPASE; CELL SURFACE RECEPTOR; MEMBRANE RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P53;

APOPTOSIS; B LYMPHOCYTE; CELL POPULATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DNA DAMAGE; DRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; TREATMENT FAILURE;

ANIMALS; APOPTOSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC;

EID: 0033759664     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1069(200009)18:3<87::AID-HON661>3.0.CO;2-8     Document Type: Review

References (67)

1. The Fas death factor
2. NF-kappaB anti-apoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 to suppress caspase-8 activation
3. Bax directly induces release of cytochrome c from isolated mitochondria
4. Programmed cell death: The influence of CD40, CD95 (Fas or Apo-I) and their ligands
5. P53: Puzzle and paradigm
6. Negative feedback regulation of wild-type p53 biosynthesis
7. Rapid ATM dependent phosphorylation of mdm2 precedes p53 accumulation in response to DNA damage
8. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage
9. Protein synthesis required to anchor a mutant p53 protein which is temperature sensitive for nuclear transport
10. A potential transcriptional activation element in the p53 protein
11. IARC database of p53 gene mutations in human tumors and cell lines: Updated compilation, revised formats and new visualisation tools
12. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family
13. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
14. P53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
15. P21 is necessary for the p53-mediated G1 arrest in human cancer cells
16. Bcl-2 interacting protein, BAG-1, binds to and inactivates the kinase Raf-1
17. bcl-2 initiates a new category of oncogenes: Regulators of cell death
18. bcl-2 blocks apoptosis in cells lacking mitochondrial DNA
19. bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death
20. A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis
21. Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity
22. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-X(L)
23. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
24. Bcl-X(L) forms an ion channel in synthetic lipid membranes
25. Channel formation by the antiapoptotic protein Bcl-2
26. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis
27. Caspases: Enemies within
28. Interleukin-1 beta converting enzyme requires oligomerization for activity of processed forms in vivo
29. Induction of mitochondrial permeability transition and cytochrome C release in the absence of caspase activation is insufficient for effective apoptosis in human leukemia cells
30. Proteasomes play an essential role in thymocyte apoptosis
31. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia
32. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias
33. Downregulation of the CD95 receptor and defective CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells
34. P53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis
35. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
36. Deficiency of ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia
37. ATM mutations in B-cell chronic lymphocytic leukemia
38. Inactivation of ataxia-telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia
39. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin
40. Cytogenetic mapping of the duplicated segment of chromosome 12 in lymphoproliferative disorders
41. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
42. Bcl-2 Gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia
43. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with induction of apoptosis and clinical outcome
44. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia
45. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2 expressing subclones
46. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance
47. Drug-induced apoptosis in chronic lymphocytic leukemia
48. Processing/activation of caspases -3 and -7 and -8 but not caspase-2 in the induction of apoptosis in B-chronic lymphocytic leukemia cells
49. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia
50. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells
51. Gene transfer of CD40 ligand induces autologous immune recognition of chronic lymphocytic leukaemic B cells
52. P53 as a target for anticancer immunotherapy
53. Gene transfer by adenovectors
54. The mdm-2 oncogene product forms a complex with the p53 proteins and inhibits p53-mediated transactivation
55. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia
56. BCL-2 antisense therapy in patients with non-Hodgkins lymphoma
57. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
58. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection
59. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX
60. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
61. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells
62. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteosome-specific inhibitor lactacystin
63. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
64. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
65. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2 chloroxyadenosine: Preclinical studies
66. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia
67. The inhibition of DNA synthesis in chronic lymphocytic leukaemia cells by chlorambucil in vitro